The FDA has delayed tolebrutinib’s review date again, as Sanofi also posted a Phase III failure for the MS candidate.
As a new week begins, the crypto market is down today, with the cryptocurrency market capitalisation decreasing by 0.5%. It ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback